Effects of early-Stress On Lipid mediators and Inflammation for early Detection of neurodegeneration (SOLID)

The Joint Research Program incorporates seven main partners in a large-scale project with total funding of approximately $CA 2 million from the European Union's Joint Research Program on Neurodegenerative Diseases (JPND). The project, which stems from the Food4BrainHealth International Research Network and the International Associated Laboratory Optinutribrain, brings together the expertise of researchers from France, Australia, the Netherlands, Hungary, Germany and Canada.

Early life stress and new biomarkers
This ambitious project will shed light on the effects of exposure to several risk factors early and later in life on lipid and inflammatory mediators, with a view to early detection of Alzheimer's disease. Through this international collaborative project, new biomarkers of cognitive decline, the impact of polyunsaturated fatty acids (omega-6 and omega-3) and their mechanisms in the brain will be studied, ultimately leading to the development of intervention strategies.


Risk factors and markers for early detection of Alzheimer’s Disease: focus on early-life stress, inflammation and lipid mediators

Duration: 36 months
Total funding: 1, 635, 428 euros

Main partners

  • Australia : Prof. Sarah J. Spencer, RMIT University
  • The Netherlands : Prof. Aniko Korosi, University of Amsterdam
  • Australia : Dr Luba Sominsky Barwon Health
  • France : Prof. Sophie Layé, NutriNeuro, Inrae, Université de Bordeaux
  • Germany : Prof. Christoph Rummel, Justus Liebig University
  • Canada : Prof. Frédéric Calon, INAF, Université Laval
  • Hungary : Prof. Peter, Budapest University of technology and Economics

External collaborators and student

See table below

About the JPND program

The European Union's Joint Program for Neurodegenerative Disease Research (JPND) is the world's largest research initiative to address the challenge of neurodegenerative diseases. JPND aims to increase coordinated investment among participating countries in research to find the causes, develop cures, and identify appropriate ways to care for people with neurodegenerative diseases.

Sarah J. SpencerRMIT University, Australiasarah.spencer@rmit.edu.au
Frédéric CalonUniversité Laval, CanadaFrederic.Calon@pha.ulaval.ca
Christoph RummelJustus Liebig University Giessen, GermanyChristoph.D.Rummel@vetmed.uni-giessen.de

Sophie Layé

Jean-Christophe Delpech

Université de Bordeaux, France



Aniko KorosiUniversity of Amsterdam, the NetherlandsA.Korosi@uva.nl
Peter AntalBudapest University of Technology and Economics, Hungaryantal@mit.bme.hu
Luba SominskyBarwon Health, Deakin University, Australialuba.sominsky@deakin.edu.au
Richard BazinetUniversity of Toronto, Canadarichard.bazinet@utoronto.ca
Anne-Louise PonsonbyThe Florey Institute, MCRI, University of Melbourne, Australiaannelouise.ponsonby@florey.edu.au
Suzanne R. de RoojiAmsterdam UMC, University of Amsterdam, the Netherlands


Jean-Christophe DelpechUniversité de Bordeaux, Francejean-christophe.delpech@inrae.fr
Carsten CulmseePhilipps-Universität Marburg Institute for Pharmacology and Clinical Pharmacy, Germanyculmsee@staff.uni-marburg.de
Bart EggenUniversity Medical Center Groningen, the Netherlandsb.j.l.eggen@umcg.nl
Peter VuillerminBarwon Health and Deakin University, Australiapeter.vuillermin@deakin.edu.au
Martin FeldottoInstitut für Veterinär-Physiologie und -Biochemie
Justus-Liebig-Universität, Allemagne
Pasindu SinghaarachchiRMIT University (Sarah Spencer)s3714630@student.rmit.edu.au



Norepinephrine Inhibits Lipopolysaccharide-Stimulated TNF-α but Not Oxylipin Induction in n-3/n-6 PUFA-Enriched Cultures of Circumventricular OrgansInt. J. Mol. Sci. 202223(15), 8745; https://doi.org/10.3390/ijms23158745